Bibliographic Details
| Title: |
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. |
| Authors: |
Jinno, Sadao1,2, Onishi, Akira3, Hattori, Shuhei4, Dubreuil, Maureen5,6, Ueda, Yo2, Nishimura, Keisuke2, Okano, Takaichi2, Yamada, Hirotaka2, Yamamoto, Wataru7, Murata, Koichi3, Onizawa, Hideo3, Ebina, Kosuke8,9, Maeda, Yuichi10, Son, Yonsu11, Amuro, Hideki11, Hara, Ryota12, Hata, Kenichiro13, Shiba, Hideyuki13, Katayama, Masaki14, Watanabe, Ryu15 |
| Source: |
Rheumatology. Feb2025, Vol. 64 Issue 2, p509-516. 8p. |
| Subject Terms: |
*BIOTHERAPY, *CLINICAL drug trials, *PATIENT compliance, *ANTI-inflammatory agents, *SECONDARY analysis, *T cells, *RHEUMATOID arthritis, *TERMINATION of treatment, *ANTIRHEUMATIC agents, *RETROSPECTIVE studies, *DESCRIPTIVE statistics, *JANUS kinases, *ANTIGENS, *MEDICAL records, *ACQUISITION of data, *DRUG efficacy, *NEUROTRANSMITTER uptake inhibitors, *COMPARATIVE studies, *CONFIDENCE intervals, *INTERLEUKINS, *CHEMICAL inhibitors, *OLD age |
| Geographic Terms: |
JAPAN |
| Abstract: |
Objectives This multicentre, retrospective study aimed to compare retention and reasons for discontinuation between Janus kinase inhibitors (JAKi) and biologic DMARDs in patients with elderly-onset rheumatoid arthritis (EORA). Methods Patients with RA enrolled in a Japanese multicentre observational registry between 2015 and 2022 were included. EORA was defined as RA with onset at age 60 or over. To adjust confounding factors by indication for initiation of TNF inhibitors (TNFi), IL-6 inhibitors (IL-6i), cytotoxic T-lymphocyte associated antigen 4 immunoglobulin (CTLA4-Ig) blockers, or JAKi, a propensity score based on baseline characteristics was used to compare drug retention. To assess the reasons for discontinuation, retention rates for ineffectiveness, adverse events and remission were analysed as secondary outcomes. Results A total of 572 patients with 835 treatment courses were identified (314 TNFi, 175 IL-6i, 228 CTLA4-Ig and 118 JAKi). After adjusting for differences in baseline characteristics, drug retention was significantly higher for IL-6i (hazard ratio [HR] = 0.38; 95% CI: 0.27, 0.55; P < 0.01) as compared with TNFi. Discontinuation due to lack of effectiveness was lower with JAKi (HR = 0.38; 95% CI: 0.22, 0.66; P < 0.01) and IL-6i (HR = 0.29; 95% CI: 0.19, 0.46; P < 0.01) as compared with TNFi although CTLA4-Ig had a similar HR to TNFi. The adjusted incidence of discontinuation due to adverse events was higher for JAKi (HR = 2.86; 95% CI: 1.46, 5.59; P < 0.01) than for TNFi. Conclusion In EORA patients, IL-6i and JAKi had longer retention and less discontinuation due to ineffectiveness than TNFi. The potential risks of JAKi should be approached with an individualized perspective. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
